Accuryn Medical Partners With Maclean Health For VA FSS Contract Award

In a significant development for veteran healthcare, Accuryn Medical has announced the inclusion of its Accuryn Monitoring System in the Department of Veteran Affairs (VA) Federal Supply Schedule (FSS). This integration marks a pivotal step in enhancing the healthcare services available to veterans across the United States. The FSS program is instrumental in fulfilling the healthcare procurement needs of the VA and other government entities, ensuring that veterans have access to the latest and most effective medical technologies.

Maclean Health, recognized for its dedication to delivering innovative products and superior customer service, is the exclusive distributor for the Accuryn Monitoring system within Federal Government Healthcare. This partnership aims to equip all 171 VA Hospitals in the U.S. with this advanced technology. Maclean Health, a certified Service Disabled Owned Small Business (SDVOSB), is at the forefront of providing state-of-the-art medical solutions to the veteran community.

John Deterding, CEO of Maclean Health, highlighted the system's advanced kidney monitoring capabilities and its proven effectiveness in reducing catheter-associated urinary tract infections (CAUTI) as key factors that streamlined the FSS application and review process. Joe Urban, CEO of Accuryn Medical and a veteran himself, expressed his satisfaction with Accuryn's inclusion in the FSS. He emphasized the importance of making cutting-edge technology accessible to veterans to optimize their care and safeguard their health during hospital stays.

The Accuryn Monitoring System is a flagship innovation designed to offer real-time continuous monitoring of urine output and intra-abdominal pressure (IAP) in critically ill patients. Its primary goal is to mitigate the risks associated with CAUTI development. By providing vital data on patients' fluid status and organ perfusion, Accuryn enables critical-care clinicians to intervene early in disease-state progression, particularly in cases of iatrogenic acute kidney injury (AKI).

Accuryn Medical, Inc., headquartered in Hayward, California, is dedicated to combating AKI through its real-time renal assessment technology. The Accuryn Monitoring System facilitates early AKI intervention, thereby reducing preventable mortality and morbidity associated with this condition. For more information about Accuryn Medical and its innovative solutions, please visit www.accuryn.com.